{
    "root": "348dbccb-f10b-8f30-e063-6394a90aee3b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoclopramide",
    "value": "20250507",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "METOCLOPRAMIDE HYDROCHLORIDE",
            "code": "W1792A2RVD"
        }
    ],
    "indications": "metoclopramide tablets indicated : treatment 4 12 weeks symptomatic , documented gastroesophageal reflux adults fail respond conventional therapy . relief symptoms adults acute recurrent diabetic gastroparesis . limitations : metoclopramide tablets recommended pediatric patients due risk developing tardive dyskinesia ( td ) extrapyramidal symptoms well risk methemoglobinemia neonates [ ( 8.4 ) ] .",
    "contraindications": "gastroesophageal reflux ( 2.2 ) administer metoclopramide continuously intermittently : continuous : administer 10 15 mg , 30 minutes meal bedtime ( maximum 60 mg per day ) 4 12 weeks . intermittent : single doses 20 mg prior provoking situation . acute recurrent diabetic gastroparesis ( 2.3 ) administer 10 mg , 30 minutes meal bedtime ( maximum 40 mg per day ) 2 8 weeks adjustment ( 2.2 , 2.3 ) gastroesophageal reflux acute recurrent diabetic gastroparesis , full prescribing information recommended reductions elderly patients , patients moderate severe hepatic renal impairment , cytochrome p450 2d6 ( cyp2d6 ) poor metabolizers .",
    "warningsAndPrecautions": "white , round , scored , debossed “ teva ” one side “ 2203 ” score side , compressed metoclopramide tablet , usp contains metoclopramide hydrochloride , usp equivalent 10 mg metoclopramide . available ndc : 70518-1193-00 ndc : 70518-1193-01 ndc : 70518-1193-02 ndc : 70518-1193-03 ndc : 70518-1193-04 packaging : 60 1 bottle plastic packaging : 30 1 blister pack outer packaging : 100 1 box inner packaging : 1 1 pouch packaging : 10 1 bottle plastic store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect light . product light sensitive . inspected discarded either color particulate observed . dispense tight , light-resistant container . keep medications reach children . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "metoclopramide contraindicated : patients history tardive dyskinesia ( td ) dystonic reaction metoclopramide [ ( 5.1 , 5.2 ) ] . stimulation gastrointestinal motility might dangerous ( e.g . , presence gastrointestinal hemorrhage , mechanical obstruction , perforation ) . patients pheochromocytoma catecholamine-releasing paragangliomas . metoclopramide may cause hypertensive/pheochromocytoma crisis , probably due release catecholamines tumor [ ( 5.5 ) ] . patients epilepsy . metoclopramide may increase frequency severity seizures [ ( 6 ) ] . patients hypersensitivity metoclopramide . included laryngeal glossal angioedema bronchospasm [ ( 6 ) ] .",
    "indications_original": "Metoclopramide tablets are indicated for the:\n                  \n                     Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy.\n                     Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.\n                  \n                  \n                     Limitations of Use:\n      \n\n \n                  Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [\n       \n \n  see Use in Specific Populations (\n                     \n                        8.4)\n       \n \n  ].",
    "contraindications_original": "Gastroesophageal Reflux ( 2.2 ) Administer metoclopramide continuously or intermittently: Continuous: Administer 10 to 15 mg, 30 minutes before each meal and at bedtime (maximum of 60 mg per day) for 4 to 12 weeks. Intermittent: Single doses up to 20 mg prior to provoking situation. Acute and Recurrent Diabetic Gastroparesis ( 2.3 ) Administer 10 mg, 30 minutes before each meal and at bedtime (maximum of 40 mg per day) for 2 to 8 weeks Dosage Adjustment in Specific Populations ( 2.2 , 2.3 ) For gastroesophageal reflux and acute and recurrent diabetic gastroparesis, see Full Prescribing Information for recommended dosage reductions for elderly patients, in patients with moderate or severe hepatic or renal impairment, and cytochrome P450 2D6 (CYP2D6) poor metabolizers.",
    "warningsAndPrecautions_original": "Each white, round, scored, debossed “TEVA” on one side and “2203” above the score on the other side, compressed metoclopramide tablet, USP contains metoclopramide hydrochloride, USP equivalent to 10 mg metoclopramide. Available in\n                  \n                  \n                  NDC: 70518-1193-00\n                  NDC: 70518-1193-01\n                  NDC: 70518-1193-02\n                  NDC: 70518-1193-03\n                  NDC: 70518-1193-04\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  OUTER PACKAGING: 100 in 1 BOX\n                  INNER PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 10 in 1 BOTTLE PLASTIC\n                  \n                  \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT.\n                  This product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed.\n                  Dispense in a tight, light-resistant container.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Metoclopramide is contraindicated:\n                  \n                     In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [\n        \n  \n   see Warnings and Precautions (\n                        \n                           5.1, \n         \n   \n    5.2)\n        \n  \n   ].\n       \n \n  \n                     When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).\n                     In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [\n        \n  \n   see Warnings and Precautions (\n         \n   \n    5.5)\n        \n  \n   ].\n       \n \n  \n                     In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [\n        \n  \n   see Adverse Reactions (\n         \n   \n    6)\n        \n  \n   ].\n       \n \n  \n                     In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [\n        \n  \n   see Adverse Reactions (\n         \n   \n    6)\n        \n  \n   ]."
}